Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity

Metastatic liver tumors have presented challenges with the use of checkpoint inhibitors (CPIs), with only limited success. We hypothesize that regional delivery (RD) of CPIs can improve activity in the liver and minimize systemic exposure, thereby reducing immune-related adverse events (irAE). Using...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) Vol. 9; no. 8; p. 807
Main Authors: Chai, Louis F., Hardaway, John C., Heatherton, Kara R., O’Connell, Kyle P., Lopes, Mikayla C., Rabinowitz, Benjamin A., Ghosh, Chandra C., Guha, Prajna, Jaroch, David, Cox, Bryan F., Katz, Steven C.
Format: Journal Article
Language:English
Published: Basel MDPI AG 21.07.2021
MDPI
Subjects:
Animal models
Antibodies
Anticancer properties
Antitumor agents
Apoptosis
Biocompatibility
Bioluminescence
Catheters
Colorectal carcinoma
Flow cytometry
Hepatocytes
Immune checkpoint
Laboratories
Liver
Liver cancer
liver metastasis
Melanoma
Metastases
Metastasis
myeloid-derived suppressor cells
PD-1
PD-1 protein
PD-L1
PD-L1 protein
Portal vein
Proteins
regional delivery
Software
Suppressor cells
systemic delivery
Toxicity
Tumor cells
Tumors
Veins
St Louis Missouri
United States > US
Germany
ISSN:2076-393X, 2076-393X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic liver tumors have presented challenges with the use of checkpoint inhibitors (CPIs), with only limited success. We hypothesize that regional delivery (RD) of CPIs can improve activity in the liver and minimize systemic exposure, thereby reducing immune-related adverse events (irAE). Using a murine model of colorectal cancer liver metastases (LM), we confirmed high levels of PD-L1 expression on the tumor cells and liver myeloid-derived suppressor cells (L-MDSC). In vivo, we detected improved LM response at 3 mg/kg on PTD7 via portal vein (PV) regional delivery as compared to 3 mg/kg via tail vein (TV) systemic delivery (p = 0.04). The minimal effective dose at PTD7 was 5 mg/kg (p = 0.01) via TV and 0.3 mg/kg (p = 0.02) via PV. We detected 6.7-fold lower circulating CPI antibody levels in the serum using the 0.3 mg/kg PV treatment compared to the 5 mg/kg TV cohort (p < 0.001) without increased liver toxicity. Additionally, 3 mg/kg PV treatment resulted in increased tumor cell apoptotic signaling compared to 5 mg/kg TV (p < 0.05). Therefore, RD of an anti-PD-1 CPI therapy for CRCLM may improve the therapeutic index by reducing the total dose required and limiting the systemic exposure. These advantages could expand CPI indications for liver tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9080807